PVCT — Provectus Biopharmaceuticals Share Price
Last trade - 00:00- $40.37m
- $43.21m
- $0.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 65.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -734.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.99 | 0.56 | 0.62 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Directors
- Edward Pershing CHM
- Timothy Scott PRE (51)
- Dominic Rodrigues VCH
- Heather Raines CFO (52)
- Bruce Horowitz COO
- Eric Wachter CTO (52)
- Webster Bailey DRC
- John Lacey DRC
- Tim Lu DRC
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 2013
- Public Since
- April 7th, 2000
- No. of Shareholders
- 809
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 420,279,879
- Address
- 800 S. Gay Street, Suite 1610, KNOXVILLE, 37929
- Web
- https://www.provectusbio.com/
- Phone
- +1 8657694011
- Auditors
- Marcum LLP
Latest News for PVCT
Upcoming Events for PVCT
Q1 2025 Provectus Biopharmaceuticals Inc Earnings Release
Provectus Biopharmaceuticals Inc Annual Shareholders Meeting
Provectus Biopharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Provectus Biopharmaceuticals Inc Earnings Release
Similar to PVCT
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 22:47 UTC, shares in Provectus Biopharmaceuticals are trading at $0.10. This share price information is delayed by 15 minutes.
Shares in Provectus Biopharmaceuticals last closed at $0.10 and the price had moved by -51.09% over the past 365 days. In terms of relative price strength the Provectus Biopharmaceuticals share price has underperformed the S&P500 Index by -54.3% over the past year.
There is no consensus recommendation for this security.
Find out moreProvectus Biopharmaceuticals does not currently pay a dividend.
Provectus Biopharmaceuticals does not currently pay a dividend.
Provectus Biopharmaceuticals does not currently pay a dividend.
To buy shares in Provectus Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.10, shares in Provectus Biopharmaceuticals had a market capitalisation of $40.37m.
Here are the trading details for Provectus Biopharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PVCT
Based on an overall assessment of its quality, value and momentum Provectus Biopharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Provectus Biopharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -8.27%.
As of the last closing price of $0.10, shares in Provectus Biopharmaceuticals were trading -10.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Provectus Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Provectus Biopharmaceuticals' management team is headed by:
- Edward Pershing - CHM
- Timothy Scott - PRE
- Dominic Rodrigues - VCH
- Heather Raines - CFO
- Bruce Horowitz - COO
- Eric Wachter - CTO
- Webster Bailey - DRC
- John Lacey - DRC
- Tim Lu - DRC